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Abstract
Background: Onchocerciasis can be effectively controlled as a public health problem by annual mass drug
administration of ivermectin, but it was not known if ivermectin treatment in the long term would be able to
achieve elimination of onchocerciasis infection and interruption of transmission in endemic areas in Africa. A recent
study in Mali and Senegal has provided the first evidence of elimination after 15-17 years of treatment. Following
this finding, the African Programme for Onchocerciasis Control (APOC) has started a systematic evaluation of the
long-term impact of ivermectin treatment projects and the feasibility of elimination in APOC supported countries.
This paper reports the first results for two onchocerciasis foci in Kaduna, Nigeria.
Methods: In 2008, an epidemiological evaluation using skin snip parasitological diagnostic method was carried out
in two onchocerciasis foci, in Birnin Gwari Local Government Area (LGA), and in the Kauru and Lere LGAs of
Kaduna State, Nigeria. The survey was undertaken in 26 villages and examined 3,703 people above the age of one
year. The result was compared with the baseline survey undertaken in 1987.
Results: The communities had received 15 to 17 years of ivermectin treatment with more than 75% reported
coverage. For each surveyed community, comparable baseline data were available. Before treatment, the
community prevalence of O. volvulus microfilaria in the skin ranged from 23.1% to 84.9%, with a median
prevalence of 52.0%. After 15 to 17 years of treatment, the prevalence had fallen to 0% in all communities and all
3,703 examined individuals were skin snip negative.
Conclusions: The results of the surveys confirm the finding in Senegal and Mali that ivermectin treatment alone
can eliminate onchocerciasis infection and probably disease transmission in endemic foci in Africa. It is the first of
such evidence for the APOC operational area.
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Onchocerciasis is a vector-borne parasitic disease caused
by the filarial worm Onchocerca volvulus. The disease is
endemic in Central and South America and the Yemen
but 99% of the disease occurs in sub Saharan Africa,
where it causes blindness and skin disease [1]. It is a
disabling disease that causes significant morbidity, psy-
chosocial problems and reduced work, especially
reduced agricultural productivity in populations affected
by the disease. About 37 million people in tropical
Africa and 140,000 others in Latin America are infected
with O. volvulus [1,2]. In many endemic countries
including Nigeria, onchocerciasis constitutes a major
public health and socio-economic problem because of
its dermal and ocular manifestations. The main strategy
for control in endemic countries is by mass ivermectin
(Mectizan
®) distribution. Following the availability of
ivermectin and its donation free of charge by Merck and
Co. to all who need it for as long as necessary [3], the
control programmes in Africa adopted mass ivermectin
distribution using community-directed treatment as its
main control strategy [4].
Large scale distribution of ivermectin started in
Kaduna State in 1991 through the community-based
method in a tripartite agreement between Sightsavers,
Kaduna State Ministry of Health and National Eye Cen-
tre, Kaduna to ensure delivery to all endemic commu-
nities. In 1997, a new partnership between Sightsavers,
Kaduna State Government, Local Governments and
endemic communities with funding from the African
Programme on Onchocerciasis Control (APOC) was set
up to implement Community Directed Treatment with
Ivermectin distribution (CDTI).
Several studies have demonstrated the effectiveness of
ivermectin as a microfilaricide, safe and good for mass
dosing with major improvement in some ocular mani-
festations of the disease [5-7]. By reducing the microfi-
larial load in the infected individuals, ivermectin
treatment prevents onchocercal blindness and skin dis-
ease, and reduces transmission of the parasite but can-
not interrupt transmission after the first few years of
treatment [8,9]. Modelling studies have predicted that
elimination of infection and interruption of transmission
is possible with annual ivermectin treatment, but that it
may take over 25 years of treatment in hyperendemic
areas [10]. However, while it has been reported that a
single dose of ivermectin is not macrofilaricidal, histolo-
gical evidence indicates that the release of microfilariae
(mf) by adult female worms is inhibited for a period of
up to one year, resulting in degeneration of intra-uterine
mf and that repeated treatment may increase the mor-
tality of adult worms [11,12]. These findings gave room
to speculate that repeated doses of ivermectin over sev-
eral years may have a cumulative effect on the fecundity
and longevity of adult worms, and thus enhance the fea-
sibility of elimination of onchocerciasis infection and
transmission in the long term.
APOC’s support to countries for implementation of
CDTI in 17 African countries in 2008 resulted in annual
treatment of 68.4 million people at risk [13], and elimi-
nation of onchocerciasis as a public health problem now
appears within reach [14]. Despite this enormous
achievement in control of onchocerciasis in Africa, there
were doubts if ivermectin could also be used to elimi-
nate infection and reduce transmission to levels at
which treatment with ivermectin could be safely
stopped. Many scientists had misgivings as to whether
onchocerciasis elimination with ivermectin is feasible in
Africa, which has more than 99% of the global cases of
infection. A 2002 conference on the eradicability of
onchocerciasis concluded that onchocerciasis elimina-
tion may be feasible in the Americas, where a strategy
of bi-annual treatment is used and onchocerciasis is
very localised, but that interruption of transmission
could not be achieved in most of Africa [15]. The con-
ference recommended that more information was
needed on the impact of ivermectin intervention on
transmission in different settings in Africa.
In 2009, Diawara et. al. provided the first evidence of
the feasibility of onchocerciasis elimination with iver-
mectin in Africa [16]. In a study in three hyper-endemic
foci in Mali and Senegal, they showed that after 15 to
17 years of six-monthly or annual treatments, only a few
infections remained in the human population and trans-
mission levels were below predicted thresholds for elim-
ination. Treatment was then stopped in test areas and
follow-up epidemiological and entomological evaluations
after 1.5 to 2 years showed no further infections or
transmission had occurred.
Following this breakthrough, APOC decided to evalu-
ate the long-term impact of ivermectin treatment in all
CDTi project areas that had at least 10 years of ivermec-
tin treatment, in order to assess the feasibility of elimi-
nation in other parts of Africa.
Two onchocerciasis foci in Kaduna State, Nigeria, had
the longest history of ivermectin treatment in the APOC
operational area. These foci were therefore selected for
the first evaluations undertaken by APOC to determine
the impact of annual ivermectin treatment on onchocer-
ciasis infection and transmission after 15 to 17 years of
treatment.
Methods
Selected onchocerciasis foci
The evaluation was carried out in two onchocerciasis
foci, one in Birnin Gwari Local Government Area (LGA),
and the second in the Kauru and Lere LGAs of Kaduna
State, Nigeria (Figure 1). The communities in these foci
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nin Gwari and Galma and Karami in Kauru and Lere.
The two foci were selected for the following reasons: i)
communities in these foci had pre-control epidemiologi-
cal data; among the areas where large-scale ivermectin
treatment was first introduced in Africa were these two
foci in Kaduna in which treatment of a sample of the
population started as part of a randomised controlled
trial of ivermectin in 1988 and 1989, and where skin-snip
surveys had been done in preparation for the trial [6,17].
ii) the foci included hyper-endemic villages, i.e. villages
with a prevalence of microfilaridermia > 60% [15-17]; iii)
t h ea r e aw a sl o c a t e da l o n gar iver with known breeding
sites of S i m u l i u md a m n o s u ms . l ., iv) the communities
had had 15 - 17 years of annual treatment with ivermec-
tin using the community-based programme since 1991,
and subsequently through the community-directed treat-
ment with ivermectin (CDTI) strategy from 1997 with
more than 65% treatment coverage.
Twenty-seven communities were selected for the eva-
luation. These communities are mainly rural with a
population range of 81 - 493 people, based on a popula-
tion census undertaken during the evaluation visit in
2008 and confirmed by the leadership of the community
and local administration. The people are predominantly
farmers and fishermen with a few engaged in petty trad-
ing. Vegetation is mainly savannah grassland, with few
areas of forest mosaic. Most of the communities, parti-
cularly in Kauru and Lere, are bordered by mountains
with fast flowing rivers and streams, some of which are
seasonal. The climate consists of two distinct seasons: a
dry season from November to March and a wet season
from April to October. During the dry season most of
the rivers become dry while in areas where the rivers
are perennial such as the River Galma, the blackflies are
few as a result of a blackfly migration to the south of
Nigeria. The rivers are reinvaded by blackfly vectors
during the rainy season.
The two evaluation areas are two distinct onchocercia-
sis foci with the highest endemicity levels in Kaduna
state. However, they are not completely isolated from
neighbouring endemic areas. Along the rivers there are
onchocerciasis endemic villages downstream from the
evaluation areas but their endemicity levels are much
lower and they are all covered by the same ivermectin
treatment programme.
Figure 1 Geographic location of the two evaluation sites in Kaduna State Nigeria.
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Onchocerciasis elimination is here defined as the reduc-
tion of local onchocerciasis infection and transmission
to such low levels that transmission can no longer sus-
tain itself and treatment can be safely stopped without
risk of recrudescence of infection and transmission [18].
Surveillance would still be needed to detect possible
reintroduction of the parasite through human or vector
migration from other endemic areas where elimination
has not yet been achieved.
To assess whether elimination of infection and inter-
ruption of transmission has been achieved, and ivermec-
tin treatment can be safely stopped, APOC has adopted
a phased evaluation that is based on the process used in
the Mali and Senegal study [18]. During the first phase
of this process, a detailed assessment is undertaken of
residual onchocerciasis infection and transmission levels
after at least 10 years of ivermectin treatment. The pre-
sent evaluation of residual infection levels in the human
population in the two onchocerciasis foci in Kaduna
State represents the epidemiological component of the
first phase. Where the evaluation results are satisfactory,
the epidemiological evaluation will be followed by an
entomological evaluation of residual onchocerciasis
transmission levels during a full transmission season
before any decision can be taken to stop treatment.
Epidemiological Evaluation
In 2008, a follow-up epidemiological evaluation was
conducted in 27 previously (1987) surveyed baseline vil-
lages in the two foci. In each selected village, geographic
coordinates were obtained using a Global Positioning
System (GPS) instrument.
Skin-snip surveys were done in all selected villages 11-
12 months after the last treatment round. In each vil-
lage, all subjects above the age of 1 year who agreed to
participate (or whose parents agree for them to partici-
pate in the case of children) and who voluntarily pre-
sented themselves at the screening centre for the survey
were asked for identification data (name, age, sex, occu-
pation, number of years resident). The surveys used
established skin-snip examination methods in which the
national onchocerciasis teams had previously been
trained by the WHO Onchocerciasis Control Pro-
gramme (OCP). Two skin biopsies were obtained from
the right and left iliac crests of all individuals who pre-
sented themselves for the survey. A 2 mm Holth cor-
neoscleral punch (Storz instrument GMBH, Heidelberg,
Germany) was used to obtain the skin biopsies. After
each series of two bloodless skin-snip obtained from a
subject, the scleral punch was sterilized sequentially in
sodium hypochlorite solution, distilled water and then
autoclaved by pressure for 15 minute. The entire pro-
cess is to ensure that HIV and other blood-borne
infections are not transferred. The samples were micro-
scopically examined after incubation for 30 minutes in
distilled water (and a further 24 hours in saline for
negative skin-snips) for the presence and number of O.
volvulus microfilariae [19,20]. The numbers of microfi-
lariae were counted and the results recorded for each
person examined. Information on the migration history
for each person during the last 10 years before the sur-
vey was also collected.
Pre- and post-treatment skin-snip data were analyzed
to determine and compare onchocerciasis infection
levels using the standard indices of prevalence of micro-
filaria and community microfilarial load (CMFL) [21].
The CMFL was used to determine the pre-control ende-
micity level of each village.
Ethical considerations
The evaluations were carried out using the WHO proto-
col for epidemiological surveillance and evaluation for
onchocerciasis control. Ethical clearance was provided
by the Kaduna State Ministry of Health after reviewing
the survey protocol and instruments for data collection.
Prior to the commencement of each survey; meetings
were held with the local authorities and community
members to sensitize them on the importance of the
evaluation, mobilize them for full participation, and
inform them about their right to decide to participate in
the examination or not. At the point of registration for
examination, verbal informed consent was obtained
from all individuals, parents or a legal guardian before
the commencement of the examination.
Treatment history
Ivermectin treatment was first introduced in the two
foci in 1988 as part of a randomised placebo-controlled
trial of ivermectin undertaken by the Kaduna-London
Onchocerciasis Collaborative Research Group to deter-
mine the impact of ivermectin treatment on visual field
loss [22]. Following the successful completion of the
trial, the Nigerian National Onchocerciasis Control Pro-
gramme (NOCP) adopted the strategy of mass drug
administration in 1991. Community-based distribution
of ivermectin started in the communities between 1991
and 1993, and from 1993 onwards all communities in
the two foci received ivermectin treatment. In 1997 the
community-directed treatment strategy of APOC was
adopted with community-selected volunteers distribut-
ing the drugs. Community treatment records show that
most eligible persons have received treatment annually
with therapeutic coverage above the minimum threshold
of 65% in the communities assessed. Information about
previous treatments was obtained from the State treat-
ment records and verified during the field visits. Table 1
shows the treatment history of the studied villages in
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77% (range 63-86%) of the total population, or about
92% of the eligible population, which is a high treatment
coverage [23].
Results
At the baseline survey (1988) a total of 6,062 subjects,
out of which 2,988 (49.6%) were male and 3,038 (50.4%)
female, participated in the survey. In the 2008 post-
intervention survey 3,703 subjects participated of whom
1,779 (48.0%) and 1,924 (52.0%) were male and female
respectively (Table 2). Out of a total census population
in 2008 of 5,806 persons for the 27 villages together,
63.8% voluntarily participated in the survey. The partici-
pation rate was higher among females (66.1%) than
among males (61.4%). The non-participants included
children below the age of 1 year (3.5% of census popula-
tion) and people who came to the examination point
but then refused to participate (0.9%), but the majority
(31.8%) were people who were registered as living in the
village but who did not come for the examination. The
non-participation rate was highest (48%) among the age
g r o u po f1 5t o2 5y e a r s ,b u td r o p p e dt oa r o u n d2 0 %
from the age of 30 years onward. Between villages, the
participation rate ranged from 40% to 80%.
Onchocerciasis infection after 15-17 years of ivermectin
treatment
In 1988, before treatment, 48% of the 6,026 subjects
examined were positive for O. volvulus microfilariae in
their skin-snip samples. The community prevalence of
O. volvulus microfilaria in the skin ranged from 23.1%
to 84.9%, with a median prevalence of 52.0%. The
CMFL ranged from 1.2 to 8.9 mf per skin-snip, with a
median of 3.9 mf overall (4.9 mf in the Birnin Gwari
focus and 3.6 mf in the Kauru/Lere focus).
In 2008, after 15 to 17 years of ivermectin treatment,
microfilariae could not be detected in the skin-snips
from any of the 3,703 subjects who participated in the
examination and the prevalence had fallen to 0% in all
27 communities (Table 3).
The results of the evaluations showed that 15-17 years
of ivermectin treatment had fundamentally changed the
epidemiological situation in the two foci (Figures 2 &3).
While onchocerciasis was highly endemic (2 villages had
ap r e v a l e n c eo fM F>7 0 % )d u ring the pre-control per-
iod in the Birnin Garbi area, after 15-17 years of treat-
ment all villages had a microfilarial prevalence of 0%. A
similar change was seen in the Kauru/Lere focus where
most villages were mesoendemic, with a prevalence of
between 40% and 65%, but where there were still four
hyperendemic villages with a prevalence greater than
65%. Again, after treatment the epidemiology had chan-
ged fundamentally with 0% prevalence throughout the
focus.
T h el a s tc o l u m ni nt a b l e3s h o w st h ep r e v a l e n c et h a t
was predicted for each village using the ONCHOSIM
simulation model for villages with the same pre-control
endemicity level and 16 years of ivermectin treatment at
70% treatment coverage. For all villages in these two
Table 1 Pre-control prevalence and Ivermectin Treatment History in 27 communities in the onchocerciasis foci of
Birnin Gwari and of Kauru/Lere in Kaduna State, Nigeria
Local Government
Area (LGA)
Year of first
Treatment
No. of evaluated
communities
Pre-control prevalence
of microfilaridermia (%)
No. of
Treatments
Mean treatment
coverage
and range (%)
Range Median
Birnin Gwari 1991 1 47.5 47.5 17 78.3
1993 4 38.9-75.0 58.8 15 78.4 (76.7-79.3)
Kauru 1991 8 46.8-67.3 56.4 17 76.2 (74.4-80.3)
1993 3 23.1-38.4 25.9 15 78.0 (76.5-80.4)
Lere 1991 5 51.3-84.6 52.7 17 77.4 (75.4-79.6)
1993 6 30.9-55.2 37.4 15 78.1 (76.9-79.4)
Total 1991-1993 27 23.1-84.6 52.7 15-17 77.7 (74.4-80.4)
Table 2 Age and sex distribution of the examined population during the baseline survey in 1987 and the evaluation
survey in 2008.
Survey Age in years Sex Total
1-9 10-19 20-29 30-49 50+ Male Female N
Pre-treatment (1987) No. examined 1,388 1,419 1,100 1,444 675 2,988 3,038 6,026
% 23.0 23.5 18.3 24.0 11.2 49.6 50.4 100
Evaluation (2008) No. examined 1,156 808 433 803 503 1,779 1,924 3,703
% 31.2 21.8 11.7 21.7 13.6 48.0 52.0 100
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fallen to 0% after 16 years of treatment, and the
observed prevalence is completely consistent with these
predictions.
Discussion
Until recently, it was doubted that onchocerciasis could
be eliminated with ivermectin treatment from endemic
foci in Africa, even though model predictions had indi-
cated that elimination might be possible in the long term
[10,15]. However, a recent study in three onchocerciasis
foci in Mali and Senegal, where treatment had started as
early as 1988/1989 with support from the former Oncho-
cerciasis Control Programme in West Africa, showed for
the first time in 2009 that elimination of onchocerciasis
u s i n gl o n gt e r mm a s sd r u ga d m inistration of ivermectin
is possible [16]. The current evaluation after 15 to 17
years of ivermectin treatment in 27 communities in two
onchocerciasis foci in Kaduna State, Nigeria, has pro-
vided further evidence that elimination of onchocerciasis
infection with ivermectin treatment is feasible in Africa
and provides the first evidence for countries supported
by APOC. Before treatment, the community prevalence
of O. volvulus microfilaria in the skin ranged from 23.1%
to 84.9% in the two foci, with a median prevalence of
52.0%. After 15 to 17 years of treatment, the prevalence
had fallen to 0% in all communities and all 3,703 exam-
ined individuals were skin-snip negative. In view of pre-
vious experiences with onchocerciasis elimination in
Africa, these findings are particularly significant. When
the Onchocerciasis Control Programme in West Africa
ceased vector control after 14 years of operations, there
Table 3 Comparison of the results of the epidemiological surveys before treatment (1987) and after 15-17 years of
treatment (2008) in the onchocerciasis foci of Birnin Gwari and of Kauru/Lere in Kaduna State, Nigeria.
Local Government Area (LGA) Village Total
number
examined
No. of
people
Infected
Prevalence
of skin
microfilariae
Community
microfilarial
load (mf/ss)
ONCHOSIM
Predicted Prevalence
1987 2008 1987 2008 1987 2008 1987 2008 2008
BIRNIN GWARI
(5)
ANGUWAN - BAWA 220 51 154 0 70.0% 0% 4.84 0 0
BARAU-BOKA 44 32 21 0 47.7% 0% 4.46 0 0
ISHWAI 120 115 90 0 75.0% 0% 8.85 0 0
KIMBI 80 118 38 0 47.5% 0% 5.22 0 0
KURBAU 265 91 103 0 38.9% 0% 4.93 0 0
KAURU
(11)
GALADIMAWA 671 235 314 0 46.8% 0% 2.87 0 0
GARMADI 423 155 220 0 52.0% 0% 4.39 0 0
JANKASA 124 118 83 0 66.9% 0% 3.91 0 0
KAGUTA 88 82 58 0 65.9% 0% 8.89 0 0
KUBAU BAUCHI 136 196 75 0 55.1% 0% 2.26 0 0
MADAM 162 117 109 0 67.3% 0% 7.95 0 0
SABON LAYI 134 117 76 0 56.7% 0% 3.76 0 0
SAYAWA 108 127 25 0 23.1% 0% 1.08 0 0
TUDUN-WADA GARMADI 276 103 106 0 38.4% 0% 2.86 0 0
ANGUWAN - SHAWARA 247 375 64 0 25.9% 0% 1.23 0 0
AKANSA 198 93 111 0 56.1% 0% 7.78 0 0
LERE
(11)
ANGUWAN TANIMU 33 77 21 0 63.6% 0% 6.02 0 0
ANGUWAN-BUZU 26 140 22 0 84.6% 0% 4.94 0 0
ANGUWAN-PAH-KURAMA 96 141 35 0 36.5% 0% 3.57 0 0
ASHEMA A 67 162 37 0 55.2% 0% 5.43 0 0
DAN-ALHAJI 524 69 162 0 30.9% 0% 2.16 0 0
KUDARU 524 224 269 0 51.3% 0% 4.59 0 0
KUDURU 572 90 277 0 48.4% 0% 1.19 0 0
UNGUWAN-PAH-HAUSAWA 164 181 53 0 32.3% 0% 1.81 0 0
WERE I 388 67 203 0 52.3% 0% 3.73 0 0
WERE II 281 167 148 0 52.7% 0% 1.62 0 0
ZARANGI 55 260 21 0 38.2% 0% 2.36 0
Total 6,026 3,703 2,895 0 48.0% 0.0% 3.93 0 0
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between 1% and 5%, but this was not enough to maintain
transmission and follow-up surveys showed that elimina-
tion had been achieved [24,25,8]. Similarly, after 15 to 17
years of ivermectin treatment in Senegal and Mali the
prevalence of microfilaria had fallen to very low levels
but in each focus there were still several villages with a
prevalence of microfilaria between 1% and 4% [16]. How-
ever, follow-up surveys after cessation of treatment
showed no evidence of renewed transmission or infec-
tion, indicating that elimination had been achieved
[16,8]. Hence, the fact that in the current surveys not a
single skin snip positive person was detected strongly
suggest that elimination has also been achieved in the
two Kaduna foci.
Nevertheless, the current evaluation involved only an
epidemiological assessment of residual infection levels in
the two foci and we consider the survey results only as
evidence for the potential of onchocerciasis elimination..
Before cessation of ivermectin treatment can be consid-
ered, the APOC operational guidelines for onchocercia-
sis elimination [18] require that, in addition to the
Figure 2 Prevalence of onchocerciasis infection in the Birnin Gwari focus, Kaduna, Nigeria, before and after 15-17 years of ivermectin
treatment.
Figure 3 Prevalence of onchocerciasis infection in the Kauru/Lere focus, Kaduna, Nigeria, before and after 15-17 years of ivermectin
treatment.
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of residual transmission levels is done during at least
one rainy season to confirm interruption of disease
transmission. Such an entomological evaluation is cur-
rently ongoing and if the results confirm the absence of
local O. volvulus transmission, the two areas in Kaduna
will be the first onchocerciasis foci in the APOC opera-
tional area where ivermectin treatment will be brought
to a successful conclusion.
A limitation of the epidemiological surveys is that a
third of the population in the selected communities did
not participate in the skin-snip examination. Though
some of these had valid reasons for non-participation
(age < 1 year, illness, absence from the village etc), for a
large majority the reasons for non-participation were
not known. This high non-participation rate could have
created a bias in the survey results if those who did not
participate in the survey were also more likely not to
have participated in ivermectin treatment. This is
another reason why an entomological evaluation of resi-
dual transmission levels is important before a final deci-
sion is taken to stop treatment in these two foci.
The treatment history is variable from village to village
depending on which of the villages were included in the
randomised controlled trial of ivermectin between 1988
and 1990. In the villages included in the trial, a ran-
domly selected proportion of the population received
the first treatment in 1988, and these individuals had up
to 19 years of ivermectin treatment by the time of the
survey. However, full community treatment with iver-
mectin was only introduced between 1991 and 1993,
and we therefore classify these two foci as having had
15 to 17 years of ivermectin treatment.
In order to achieve elimination in an onchocerciasis
endemic focus, many years of ivermectin treatment are
required [10,26]. One reason for this is that the adult
onchocercal parasites live for about 14 years [27]. But
there are other factors that determine how many years
of treatment are needed in a given focus. A critical fac-
tor is the pre-control endemicity level which reflects
the initial worm load and the pre-control intensity of
transmission [21,28]. As indicated in table 2 the CMFL
in the villages in the two foci ranges from 1.2 to 8.9
mf per skin-snip, with a median of 3.9 mf per snip,
which classifies these foci as mesoendemic [29]. The
ONCHOSIM model predicts that with such low ende-
micity levels, onchocerciasis elimination can be
achieved by 10 to 15 years of annual ivermectin treat-
ment with good (> 75%) treatment coverage [10].
Therefore, even though we evaluated the project after
15 to 17 years of treatment with ivermectin we antici-
pate that the project had already achieved elimination
earlier.
Conclusion
APOC pioneered the strategy of CDTI which empowers
communities to direct their own health care. This strat-
egy appears to have achieved onchocerciasis elimination
in two onchocerciasis foci in Kaduna State, Nigeria.
This is the first such documented example of elimina-
tion in the APOC operational area in Africa. If the
planned entomological evaluations in these two foci
confirm interruption of transmission, ivermectin treat-
ment will be stopped, making these two foci the first in
any APOC country where ivermectin treatment in an
onchocerciasis endemic area has been brought to a suc-
cessful conclusion.
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